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ABSTRACT
La-related protein 1 (LARP1) regulates the stabil-
ity of many mRNAs. These include 5′TOPs, mTOR-
kinase responsive mRNAs with pyrimidine-rich 5′
UTRs, which encode ribosomal proteins and trans-
lation factors. We determined that the highly con-
served LARP1-specific C-terminal DM15 region of
human LARP1 directly binds a 5′TOP sequence. The
crystal structure of this DM15 region refined to 1.86
A˚ resolution has three structurally related and evolu-
tionarily conserved helix-turn-helix modules within
each monomer. These motifs resemble HEAT re-
peats, ubiquitous helical protein-binding structures,
but their sequences are inconsistent with consen-
sus sequences of known HEAT modules, suggesting
this structure has been repurposed for RNA inter-
actions. A putative mTORC1-recognition sequence
sits within a flexible loop C-terminal to these repeats.
We also present modelling of pyrimidine-rich single-
stranded RNA onto the highly conserved surface of
the DM15 region. These studies lay the foundation
necessary for proceeding toward a structural mech-
anism by which LARP1 links mTOR signalling to ri-
bosome biogenesis.
INTRODUCTION
La-related protein 1 (LARP1) is implicated in the stabil-
ity, localization, and translational efficiency of mRNAs re-
quired for cell development, migration, division, and gen-
eral translation (1–6). LARP1 alters the association of mR-
NAs with polysomes and pre-polysomes, and decreases the
migratory potential of cells (3,5,7). Its localization to the
leading edge of cells combined with its role in translation
suggests that LARP1 may play a role in directing localized
protein synthesis (3). Upregulation of LARP1 occurs in sev-
eral cancers, including that of the liver (8–11), cervix (12)
and breast (13,14), and is correlated with tumor progression
and adverse clinical outcome (12).
LARP1 plays conserved roles in regulating the stability
of mRNAs across the animal and plant kingdoms. For ex-
ample, in Caenorhabditis elegans, LARP1 localizes to P-
bodies where it is thought to regulate the levels of Ras-
MAPK mRNAs during oogenesis (15). Similarly, through
its interaction with poly(A) binding protein (PABP), which
directly binds the 3′ poly(A) tails of mRNAs, Drosophila
LARP1 plays roles in fertility and embryonic development
(2,4). This direct PABP interaction is conserved in human
cells (1,3), where LARP1 has also been observed to local-
ize to stress granules (16). In Arabidopsis, LARP1a par-
ticipates in destabilizing mRNAs as part of the XRN4
exoribonuclease-associated heat stress response (17).
Several lines of evidence indicate that LARP1 is an RNA
binding protein. While data suggests LARP1 can associate
with poly-adenylate, uridylate, and guanylate sequences
(1,15), it has been shown to preferentially associate with
the 5′ ends of mRNAs containing terminal oligopyrimidine
tracts (5′TOPs) (1,5,16). Immediately after the 5′ cap, the
5′TOP motif has 4–14 pyrimidine residues followed by a
GC-rich region (18). mRNAs containing these sequences
are known as TOP mRNAs and encode most translation
factors and ribosomal proteins (18), which are essential for
supporting cell growth and proliferation.
Accordingly, the oncogenic growth-response mTOR ki-
nase regulates the expression of TOPmRNAs. mTOR com-
plex 1 (mTORC1) transduces growth signals to activate the
translation of ribosomal and ribosome-associated mRNAs,
thereby stimulating ribosome biogenesis and cell prolifer-
ation (7). For this reason, and because of its involvement
in signalling cascades that are often disrupted in cancer,
mTOR and components of its pathways are attractive anti-
cancer drug targets. Although mTOR inhibitors are effec-
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tive in the treatment of some rare tumours, for the major-
ity of cancers, their inability to potently target ribosome
biogenesis, inhibit proliferation and cause apoptosis has
limited their efficacy. Additionally, inhibition of mTORC1
causes feedback activation of PI3K/AKT, Ras/MAPKand
mTORC2 signalling cascades. This results in a paradoxical
increase in protein biosynthesis, cell cycling and the emer-
gence of resistance (19–22).
Although mTORC1 signalling regulates TOP mRNA
translation, neither mTOR itself, nor any of the subunits
within its active complexes (mTORC1 and mTORC2), has
been shown to directly interact with 5′TOPs (18). Recent
data have identified LARP1 as an mTORC1 substrate that
binds 5′TOPs to enhance their translation (5,18) and as a
target ofmTORkinase throughmutual associationwith the
Raptor subunit of mTORC1 (5,16). This positions LARP1
as the integrator in the mTOR-TOP signalling axis and
directly links it to ribosome biogenesis (19–22). Further,
its downstream location within the mTORC1 cascade and
its direct control over proliferation via TOP regulation (5)
makes LARP1 a potential anti-cancer target.
La and its related proteins, so named because they carry
an eponymous ‘La motif ’ that adopts a winged helix-turn-
helix fold (23–26), exist in all eukaryotes and can be divided
into subfamilies based on the conservation of sequence be-
yond the La motif. Most of these subfamilies retain at least
one RNA recognition motif (RRM) C-terminal to the La-
motif (27). LARP1, the largest member of the LARP fam-
ily, contains an RRM with a predicted  fold, hav-
ing characteristic secondary structural element lengths con-
served across all LARP1 proteins (27). LARP1 also in-
cludes a highly conserved LARP1-specific region in its C-
terminus that contains at least one DM15 box (also referred
to as a unit, motif, module or repeat) (15,27,28). These units
are well conserved among species, with at least 50% simi-
larity in amino acid sequence across more than 90% of the
identified LARP1 proteins (27). Until now, the DM15 re-
gion in human LARP1 had been predicted to be comprised
of two such units, boxes, or modules (A and B) that are
present in LARP1 proteins throughout evolution and have
most likely arisen through duplication (27). Other organ-
isms, including plants, contain three DM15 modules, de-
noted A, B and C.
Here, we present the first evidence that the DM15 region
of human LARP1 mediates its RNA binding activity. We
also present the crystal structure of the DM15 region from
human LARP1, the first structure fromLARP1, which pro-
vides evidence for its RNA-binding capabilities. Our crystal
structure reveals three structural repeats that correspond to
threeDM15modules, whichwe have found to exist in nearly
all LARP1 protein sequences. Importantly, because the ex-
pression of LARP1 is upregulated in several cancers and
the conserved C-terminal LARP1-region is predicted to be
exclusive to LARP1, our crystal structure reveals a unique
target for future drug design studies.
MATERIALS AND METHODS
Protein cloning, expression and purification
The DM15 region (DM15) of the LARP1 coding sequence
(amino acids 796–946 from isoform LARP1a) used in x-
ray crystallography and biochemical studies was cloned by
PCR from full-length LARP1 coding sequence (accession
number BC001460.2) into a modified pET28 vector. The re-
sulting construct expressedDM15with anN-terminalHis6-
MBP tag followed by a Tobacco Etch Virus protease cleav-
age site and glycine-linker. Plasmids expressing point mu-
tants of DM15 were generated using site-directed mutagen-
esis.
Expression plasmids were transformed into BL21(DE3)
Escherichia coli cells and grown overnight on LB agar plates
supplemented with 30 g/ml kanamycin. The His6-MBP-
DM15 fusion protein was expressed by scraping a ∼75%
confluent plate of transformed E. coli into 750 ml autoin-
ductionmedia (29), culturing for 3 h at 37◦C, and thenmov-
ing cultures to 18◦C for 18 h. Cells were collected, flash
frozen in liquid nitrogen, and stored at −80◦C.
Cells were resuspended in lysis buffer (50 mM Tris–HCl,
pH 7.5, 400 mM NaCl, 10 mM imidazole, 10% v/v glyc-
erol) with Complete EDTA-free protease inhibitor tablets
(Roche) and 4mgml−1 lysozyme. Cells were lysed by a com-
bination of freeze-thaw and homogenization, and the result-
ing lysate was clarified by centrifugation. His6-MBP-DM15
was purified in batch by nickel agarose affinity chromatog-
raphy (ThermoScientific) and eluted with 50mMTris–HCl,
pH 7.5, 400 mM NaCl, 250 mM imidazole, 10% glycerol.
The His6-MBP tag was removed by 2 mg TEV protease di-
gestion overnight at 4◦C during dialysis into 50 mM Tris–
HCl, pH 8, 150 mM NaCl, 0.5 mM EDTA, 10% glycerol.
Nucleic acid and protein contaminants were removed by
tandemHiTrapQ andHiTrap SP ion exchange (GEHealth-
care Lifesciences); DM15 free of nucleic acid contamination
was eluted off the HiTrap SP column with a NaCl gradient
(150 mM–1 M) over 10 cv. The fractions containing DM15
were pooled and brought to 1Mammonium sulfate, 50mM
Tris–HCl, pH 7 and loaded onto a 5 ml butyl HP column
(GE Healthcare Lifesciences). The butyl HP column was
eluted in 50 mMTris–HCl, pH 7, 2 mMDTT. The fractions
containing DM15 were concentrated and buffer exchanged
using a 10K MWCO concentrator in 50 mM HEPES, pH
7, 2 mM DTT to a final concentration of 20 mg ml−1 for
crystallography or in 50 mM Tris–HCl, pH 7.5, 250 mM
NaCl, 25% glycerol, 2 mMDTT to a final concentration of
2 mg ml−1 for biochemistry. Point mutants of DM15 were
purified and stored in the same manner as WT.
Selenomethionine-derivatized DM15 (Se-met) autoin-
duction (29) and protein purification were performed as de-
scribed above, with the addition of 2 mMDTT throughout
the prep after nickel affinity chromatography. Se-met pro-
tein was concentrated to 18 mg ml−1.
Crystallization and structure solution
DM15 crystals were grown by hanging drop vapor diffu-
sion at room temperature overnight using a 1:1 protein
to mother liquor ratio against a reservoir solution of 0.15
M sodium thiocyanate, 17% PEG 3350 (optimized from
JCSG+ [Qiagen] condition 14). Native crystals were cry-
oprotected by equilibration to 0.15 M sodium thiocyanate,
25% PEG 3350, 10% glycerol.
Se-met crystals were grown by hanging drop vapor dif-
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tein to mother liquor ratio against a reservoir solution of
0.2 M ammonium nitrate, 20% PEG 3350 (optimized from
JCSG+ [Qiagen] condition 27). Se-met crystals were cry-
oprotected by equilibration to 0.2 M ammonium nitrate,
25% PEG 3350.
X-ray crystallographic data was collected at the National
Synchrotron Light Source (Brookhaven National Lab).
Single-anomalous dispersion of Se-met crystals was used
to phase the structure in Phenix (30). Non-crystallographic
symmetry averaging combined with solvent flattening was
then used to generate an interpretable map (30). Models
were built with Coot (31) and refined with Phenix (30). Fi-
nally, the resolution of the derivative data was extended by
using the experimentally derived structure as a searchmodel
for molecular replacement (30) into a native dataset that
was truncated at 1.86 A˚ resolution. Simulated annealing
composite omit maps were used to confirm amino acid reg-
ister (Phenix (30), CCP4 (32)). Iterative building and refine-
ment were performed in Coot (31) and Phenix (30), respec-
tively. Figures were generated with the PyMOL Molecular
Graphics System (Schro¨dinger, LLC.).
RNA sequences
RNA oligonucleotides used in the biochemical as-
says contained the following 5′-3′ sequences: A16
(AAAAAAAAAAAAAAAA) (Sigma), U16 (UUUU-
UUUUUUUUUUUU) (Sigma), RPS6–20mer (CCU-
CUUUUCCGUGGCGCCUC) (Sigma), RPS6–42mer
(CCUCUUUUCCGUGGCGCCUCGGAGGCGU-
UCAGCUGCUUCAAG) (T7 in vitro transcribed),
RPS6 TOP (GUGGCGCCUCGGAGGCGU-
UCAGCUGCUUCAAG) (T7 in vitro transcribed),
PABPC1 (CCCCUUCUCCCCGGCGGUUA) (Sigma),
RPL13A (CACUUCUGCCGCCCCU) (IDT).
Electrophoretic mobility shift assays
RNA oligos were 5′-end labelled with [ -32P]-ATP (Perkin
Elmer) using T4-polynucleotide kinase (New England Bi-
olabs) and gel purified. 5X protein stocks were prepared
in protein dilution buffer (50 mM Tris–HCl, pH 7.5, 250
mM NaCl, 25% glycerol, 2 mM DTT). Binding reactions
contained final concentrations or amounts of 20 mM Tris–
HCl, pH 8, 150 mM NaCl, 10% glycerol, 1 mM DTT, 0.5
g tRNA (Life Technologies), 1 g BSA and<2 nMRNA.
Wild-type DM15, R840E and Y883A proteins were titrated
at 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 M; GQ908–909AA
protein was titrated at 0, 0.5, 1, 5, 10, 20, 50, 100, 150 M.
Reactions were incubated on ice for 30 min and loaded on
7–8% polyacrylamide (29:1) native 0.5× TBE gels at 4◦C.
Gels were run at 120 V for 40 min at 4◦C, dried, and ex-
posed overnight. Exposed phosphor screens (GE Health-
care Lifesciences) were imaged on a Typhoon FLA plate
reader (GE Healthcare Lifesciences) and quantitated us-
ing Imagequant TL (GEHealthcare Lifesciences). Fraction
shifted was calculated by taking the ratio of the sum of
the background-corrected volume intensities for all bands
above the unshifted probe over total counts per lane.
Sequence alignments
Sequences were aligned using the multiple sequence com-
parison by log-expectation (MUSCLE v3.7) software (33)
and represented using JalView (34).
Cross-linking
DM15 was incubated with trace amounts of radiolabelled
oligonucleotide in 150 mM NaCl, Tris–HCl, pH 8, 1 mg
ml−1 BSA and exposed to 254 nm UV light for 30 min or
over a time course of 0–90 min. Each crosslinking reaction
was analysed by SDS-PAGE on a 15% polyacrylamide gel
(37.5:1) and visualized by phosphor screen.
Size exclusion chromatography
All samples were run and absorbance data (280 and 254
nm) recorded on anAkta Pure chromatography system (GE
Healthcare Lifesciences). Samples (90 g DM15; 23 g
DM15 + 7.4g RPS6 oligonucleotide (1:1 molar ratio) pre-
incubated on ice for 20 min; 7.4 g RPS6 oligonucleotide;
or molecular weight standards (BioRad)) were analysed
with a HiLoad 16/600 Superdex 75 pg column (GEHealth-
care Lifesciences) in 50mMTris–HCl, pH 8, 200mMNaCl,
1 mM DTT, 2% glycerol.
Nuclease probing
RNA oligos were 5′ end labelled with [ -32P]ATP (Perkin
Elmer) using T4-polynucleotide kinase (NEB) and gel pu-
rified. 5X protein stocks were prepared in protein dilution
buffer (50 mM Tris–HCl, pH 7.5, 250 mMNaCl, 25% glyc-
erol, 2 mM DTT). All reactions contained 0.5 g tRNA
(Life Technologies), 1 g BSA, and 10 000 counts/l radi-
olabelled RNA. Binding reactions were incubated at room
temperature for 30 min prior to the addition of RNase. Di-
gestion reactions were conducted for 10 min at room tem-
perature and were stopped with formamide loading dye
and loaded directly on 12% polyacrylamide (29:1) 1× TBE
7M urea gels, which were run at 90 W for 45 min. Gels
were dried, exposed overnight and phosphor screens (GE
Healthcare Lifesciences) were imaged with a Typhoon (GE
Healthcare Lifesciences).
RNaseT1: 5′-end labelled RNA was incubated with
DM15 (0–20 M) for 30 min at room temperature prior to
the addition of 0.1 unit of RNaseT1 (ThermoScientific).
RNase A: 5′-end labelled RNA was incubated with 0 or
10 MDM15 for 30 min at room temperature. Serial dilu-
tions of RNase A (ThermoScientific) were tested for each
reaction: 0, 0.001 ng, 0.005 ng, 0.01 ng, 0.05 ng, 0.1 ng.
The hydroxyl RNA ladder was generated by incubating
10 000 counts of 5′ end-labelled RNA in 50 mM sodium
carbonate, pH 11.7, 1 mMEDTA. Reactions were heated at
95◦C for 4 min and incubated on ice for 5 min. The RNase
T1 ladder was generated by digesting 10 000 counts of 5′
end-labelled RNA in 25 mM sodium citrate, pH 5.5, 7M
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RESULTS
The human DM15 motifs interact directly with RNA
The DM15 region (DM15) of LARP1 has highly conserved
motifs of unknown function. While several publications
have reported an RNA binding activity of the C-terminal
conserved region of LARP1 (1,15), the methods utilized
were complicated by the presence of other cellular compo-
nents. To overcome this, we conducted direct in vitro RNA
binding assays of the humanDM15 using amino acids 796–
946 from the LARP1a isoform (corresponding to amino
acids 873–1023 in the longer isoform 2 (13) of LARP1) (Fig-
ure 1A and B). Since LARP1 has been implicated in bind-
ing both the 5′ and 3′ ends of mRNA targets, we tested an
oligonucleotide representing the 3′ poly(A) tail and RNA
oligonucleotides from the 5′ untranslated region of the mR-
NAs encoding RPS6 (1), RPL13A and PABPC1 (5). These
5′TOPs had previously been identified as LARP1 interac-
tors (1,5,16). We also tested the cognate poly-U RNA bind-
ing sequence of genuine La protein, the first identified and
best studied La-motif containing protein (35).
Electrophoretic mobility shift assays conducted with
an oligonucleotide representing the 5′TOP sequence from
RPS6 (RPS6 42-mer) demonstrate that DM15 directly
binds this sequence in two concentration-dependent com-
plexes (see below). DM15 did not interact with a related
olignonucleotide lacking the polypyrimidine tract (RPS6
TOP), suggesting DM15 specifically recognizes at least
the 5′ pyrimidine-rich region of this sequence (Figure 1A).
These data also suggest that the DM15 region largely sup-
ports the LARP1 interaction with the RPS6 5′TOP re-
ported by Fonseca et al. (16).
DM15 did not bind the oligonucleotides representing
the first sixteen or twenty nucleotides of the 5′TOPs from
RPL13A or PABPC1 (data not shown), respectively. The
RPL13A and PABPC1 sequences have a shorter and longer
polypyrimidine stretch, respectively, compared to that in the
RPS6 (5) and RPL32A (16) sequences. These observations
might hint at an optimal polypyrimidine length for DM15
recognition.
RNase probing assays reveal that DM15 protects nu-
cleotides CUUUUC and GGCG of the RPS6 5′TOP
sequence, expanding its recognition motif beyond the
polypyrimidines (Supplementary Figure S1). Consistent
with this observation, DM15 cannot shift shorter oligonu-
cleotides representing only the first 8 or 11 nucleotides of the
RPS6 5′TOP sequence (data not shown), but can shift a 20-
mer (Figure 1A), suggesting a requirement for the 3′ G-rich
end of this motif. Quantification of the interaction of the
DM15 construct with this 20-mer oligonucleotide reveals
an affinity of 776 ± 26 nM (∼500 nM when corrected for
active protein concentration) in the presence of non-specific
competitor molecules (Figure 1C). No specific binding was
observed for either the poly(U) (U16) or the poly(A) (A16)
oligonucleotide (data not shown). UV and glutaraldehyde
cross-linking experiments and analytical gel filtration sug-
gest that one or two molecules of DM15 can interact with
one RNA molecule comprised of 16–20 nucleotides (Sup-
plementary Figure S2 and data not shown).
The DM15 region contains three helix-turn-helix HEAT-like
repeats
To understand the mechanism of its RNA binding activity,
we determined the crystal structure of DM15 from human
LARP1 to 1.86 A˚ resolution (Table 1), using the same con-
struct we used in the binding studies. The crystal structure
contains four copies of DM15 in the asymmetric unit in two
pseudo-dimers; ∼98% of the amino acids are ordered and
visible in the experimental map. Superposition of all four
copies based on C positions yields a range of root-mean-
square deviation (RMSD) among six pair-wise permuta-
tions of 0.29–0.95 A˚ (Supplementary Figure S3), with the
majority of the differences appearing within the C-terminus
of the construct.
DM15 of human LARP1 folds into two layers of alpha
helices, with each layer containing three or four parallel
alpha helices whose axis is offset from the helical axis of
the other layer by ∼40◦ (Figure 2) (36). The helices par-
tition into layers in an alternating fashion, with the even
helices forming one layer, and the odd helices forming the
second layer; the C-terminal helix of this construct, 8,
lays approximately orthogonally to both layers. An edge-
on view of the molecule reveals that the helices pack into a
curved structure, creating concave and convex surfaces (Fig-
ure 2A, right). Themonomer appears to have a pseudo-two-
fold symmetrical organization about its center, although the
capping helices do not conform to this pseudo-symmetry.
One of the four copies of the molecule in the asymmetric
unit has a four-residue helical turn between 7 and 8 (Sup-
plementary Figure S3).
A search of the structural database with the DALI
server (37) reveals that the helix-turn-helix repeats con-
tained within DM15 are structurally similar to tetratri-
copeptide repeats (TPRs). However, the angles between se-
quential helices differ in DM15 as compared to the angles
observed in ideal TPRs (38) and the sequence of each repeat
is inconsistent with the consensus sequence of TPRs (39).
Likewise, the sequences of these repeats do not align with
the consensus sequences of other helix-turn-helix repeats,
like HEAT repeats (40) or pentatricopeptide repeats (41).
Additionally, the lengths of the repeats in DM15 are incon-
sistent with the lengths of repeats in these modules. How-
ever, at least two of the three structural repeats in DM15 ap-
pear to contain a kinked-alpha helix, consistent withHEAT
repeats.
Sequence conservation of the third DM15 box
The human DM15 region of LARP1 was predicted to con-
tain two evolutionarily conserved amino acid sequences,
DM15A and DM15B (27). Sequence assignment of the al-
pha helices indicates that the conserved DM15A element
occupies 2 and 3 and the DM15B element lies within 4
and 5 (Figure 2B). Helices 6 and 7 form a structural repeat
that packs against the DM15A and B repeats and contains
elements of both the DM15A and DM15B consensus se-
quences (Figure 2B,C). Therefore, human LARP1 contains
three DM15 boxes.
Having observed these three structural DM15 repeats
in human LARP1, we examined the conservation of these
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Figure 1. DM15 binds the 5′TOP sequence of RPS6. (A) Representative EMSAs of WT DM15 with oligonucleotides containing the first 42 nucleotides
of the RPS6 5′TOP (RPS6-42mer; top), the RPS6 TOP lacking the 5′ polypyrimidine tract (RPS6 TOP; middle), and the first 20 nucleotides of the
RPS6 5′TOP (RPS6-20mer; bottom). (B) EMSAs of point mutants of DM15 at the putative DM15 RNA-binding and non-crystallographic dimerization
surfaces. RNA binding of these point mutants was tested with the RPS6-20mer oligonucleotide. (C) Quantification of three independent EMSAs of wild-
type DM15 bound to radiolabelled RPS6-20mer RNA oligonucleotide; error bars show standard deviation. In (A) and (B), asterisks denote 1 M total
protein for reference.
S4). We aligned the DM15 region of LARP1 proteins from
71 representative plant, protist, fungi and animal species
(Supplementary Figure S4). We observed that the third
DM15 repeat of the human protein is highly homologous
to the DM15C box, previously proposed to be specific to
plants (27). In fact, in all eukaryotes, except for Ascomy-
cota fungi, LARP1 possesses three related, well-conserved,
DM15 boxes (A–C). Sequence alignment of each box in-
dependently (Figure 3A–C), and of the three consensus se-
quences (Figure 3D), strongly suggests that these elements
evolved in a concerted manner from a single common an-
cestral motif. Sequence conservation in the DM15 region is
centered on the three DM15 repeats, with short N- and C-
terminal extensions that encompass the first and last helices
found in the human protein. Although Ascomycota fungi
LARP1 do not present a conserved DM15C element and
possess less well-conserved DM15A and B elements, this
DM15 region is still predicted to fold in a similar fashion
to the human protein (data not shown), suggesting a con-
served structural organization.
Conserved residues map to a positively charged surface
Electrostatic profile calculations mapped onto the surface
representation of the crystal structure of DM15 reveal two
positively charged patches (Figure 4), one on each side
of the curved molecule. One of these patches contains
several amino acids that are identically conserved in 90–
100% of LARP1 proteins examined (27,42) (see Supple-
mentary Figure S4). This patch resides on the concave side
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Table 1. Data collection, phasing and refinement statistics
Se-Met Native
Data collection
Space group P21 P21
Unit cell dimensions
a, b, c (A˚) 76.7, 61.5, 83.2 77.9, 61.8, 85.3
β (◦) 115.5 116.2
Resolution (A˚) 50–1.8 50–1.62
Rmerge (%) 9.6 (9.1) 15.3 (10.8)
I/(I) 34.2 (2.25) 34.6 (1.06)
Completeness (%) 99.9 (99.9) 94.7 (63.7)
Redundancy 6.4 (3.0) 5.4 (2.4)
Wavelength (A˚) 0.979 1.10
Unique reflections 35 696 87 976
Phasing
Method SADa MRb
Resolution range 42.6–2.2 38.3–1.86
No. sites/copiesc 8 4
FoMd 0.484 N/A
Refinement
Resolution (A˚) 42.6–2.20 38.3–1.86
Rwork/Rfree 17.4/22.2 17.9/21.5
RMSD bond angle (◦) 0.991 0.921
RMSD bond length (A˚) 0.008 0.007
Average B-factor (A˚2) 31.5 25.7
PDB ID 5C0V 4ZC4
aSAD: single wavelength anomalous dispersion.
bMR: molecular replacement.
cnumber of selenium sites found (SAD) OR number of search models placed (MR).
dFoM, figure of merit (SAD).
and curved structures containing helix-turn-helix repeats
(39,40,43) that typically supports intermolecular interac-
tions. Biochemical analysis of conserved amino acids in the
patch on the concave side is consistent with their participa-
tion in RNA binding; mutations R840E and Y883A oblit-
erate RNA binding (Figures 1, 3 and 4).
The DM15 region is a monomer in solution
The four copies of DM15 in the asymmetric unit parti-
tion into two ‘V’-shaped dimers. A sulfate ion mediates
each dimer through direct, symmetric interactions with
conserved Tyr911 and Lys915 (Figures 3 and 5) of each
molecule. Thus, a pseudo-twofold axis of symmetry passes
through each sulfate ion approximately perpendicular to the
plane of the 8 helices. The more highly conserved surface
of each monomer faces the symmetry axis, forming a deep,
positively charged cleft in which the co-crystallized sulfate
ion binds. The two dimers superimpose with an RMSD of
0.806 A˚ over 282 Cs (Supplementary Figure S3).
The twomonomers of DM15 interact throughmore than
thirty hydrophobic, ionic and hydrogen-bonding interac-
tions (Supplementary Figure S5), several of which involve
conserved amino acids (44,45) and are pseudo-symmetric.
For example, the side chain of Q909, conserved in animals
and a polar residue in other organisms (Figure 3, Supple-
mentary Figures S4 and S5), interacts with the backbone
chemical groups of Gly869 and Arg871 in each molecule. In
addition, the side chain of Tyr872 from one copy interacts
with the side chain of Leu910 in the other copy (Figure 3,
Supplementary Figure S5).
We next probed the biological relevance of this dimeriza-
tion interface. As mentioned above, mutation of amino acid
Arg840 or Tyr883 eliminates RNA binding (Figure 1B);
based on their positions relative to the dimerization inter-
face (Supplementary Figure S5), Tyr883 most likely par-
ticipates in RNA binding, whereas Arg840 might partici-
pate in both RNA binding and dimerization. A construct
with alanine substitutions for two amino acids that reside at
the dimerization interface but not near the predicted RNA
binding site (G908 and Q909; Supplementary Figure S5F),
retains RNA binding and has a two-state shift profile simi-
lar to that of wild-type DM15, presumably representing the
1:1 and 1:2 RNA:protein stoichiometries (Figure 1B); this
mutant was less stable upon purification and required more
protein to achieve a maximum probe shift (see methods).
We also directly assessed the oligomeric state of wild-type
DM15. In the absence of RNA, DM15 elutes in a size ex-
clusion chromatography experiment as a monomer, even in
the presence of sulfate ion (data not shown). However, more
than one RNA-bound complex elutes in the presence of the
RPS6 5′TOP (Supplementary Figure S2). Consistent with
this observation, UV and glutaraldehyde crosslinking con-
ducted over a range of protein concentrations suggest that
one or twomolecules ofDM15 can bind a singlemolecule of
RNA (Supplementary Figure S2 and data not shown). Ad-
ditionally, RNase footprinting ofDM15 bound to theRPS6
5′TOP 20-mer oligonucleotide reveals 6 and 4 protected nu-
cleotides, separated by three unprotected nucleotides (Sup-
plementary Figure S1); based on the dimensions of DM15,
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Figure 2. The humanDM15 region contains three helix-turn-helix repeats. (A) Ribbon diagram of the structure of LARP1 amino acids 796–946. The eight
alpha helices observed are labelled numerically from N- to C-terminus. The two layers of helices are coloured yellow and orange; the loops and the helix
(8) that does not lie parallel to other helices are shown in white. The left panel is related to the right panel by a rotation about the x-axis of ∼95◦. (B) The
DM15 region contains three helix-turn-helix repeats. DM15A is shown in brown, DM15B in purple, DM15C in pink. (C) Alignment of three structural
repeats, coloured as in (B).
concave surface, suggesting that two molecules of DM15
might bind a single RNA substrate at higher protein con-
centrations. Alternatively, two populations of DM15-RNA
might exist, with one site protected in one population and
the other site protected in the second population.
Therefore, our data are consistent with a monomeric
DM15 in the absence of RNA and the ability of up to
two molecules of DM15 to bind the RNA oligonucleotides
tested. However, we cannot exclude the possibility that
LARP1 is a dimer in solution or in the cell. Additionally, it
remains to be determined if there is a concentration depen-
dence on the LARP1:RNA stoichiometry in the cell, since
in cancer cells, in particular, there is a significant increase in
LARP1 expression (12).
DISCUSSION
La-related protein 1 (LARP1) belongs to the ubiqui-
tous family of La-related proteins, which controls the
metabolism ofmanyRNAs in the cell (46). LARP1 has been
implicated in regulating mRNA stability and localization
(2–4,17). Levels of LARP1 are upregulated in breast, cer-
vical, and liver cancers and the protein is tumorigenic (12).
Until now the detailed mechanism of LARP1 function has
remained largely uncharacterized.
LARP1 has been linked to ribosome biogenesis via in-
teraction with TOP mRNAs, which encode ribosomal pro-
teins and translation factors, and whose translation is reg-
ulated by mTOR kinase (5,16). It has been postulated that
LARP1 acts downstream of mTORC1 and as a direct in-
teractor with TOP mRNAs. However, the exact site of its
interaction with these transcripts has remained elusive (5).
Here, we report the first direct RNA-binding ability of the
LARP1-specificRNAbinding domain containedwithin the
DM15 boxes and present structural data of this domain that
provides insight into its RNA binding functions and begins
to address the mechanism of its regulation by mTOR.
Each La-related protein has a cognate RNA binding se-
quence. Until now, the cognate binding sequence of LARP1
has remained unclear. We have shown that the LARP1-
specific DM15 region, a sequence that is highly conserved
among LARP1 proteins, but does not appear anywhere
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Figure 3. Alignment of the LARP1 DM15 region from plant, protista, fungi and animal species. Alignment of the (A) DM15A, (B) DM15B and (C)
DM15C repeats from select plant, protist, fungi and animal species. (D) Alignment of the DM15 A, B and C consensus sequences. Black asterisks, amino
acid targeted by mutagenesis (Figure 4). Red asterisks, amino acids that mediate dimer interactions through the co-crystallized sulphate ion (Figure 5).
The numbers above each alignment indicate the position in the human LARP1a sequence. The intensity of the sequence colouring is proportional to
the level of conservation. The species code is the following: Animal: Dm: Drosophila melanogaster, Dr: Danio rerio, Hs: Homo sapiens, Ta: Trichoplax
adhaerens. Fungi: Aspwe: Aspergillus wentii, Batde: Batrachochytrium dendrobatidis, Phybl: Phycomyces blakesleeanus.Plant and algae: At: Arabidopsis
thaliana, Cr: Chlamydomonas reinhardii. Protista: Mb: Monosiga brevicollis, Dd: Dictyostelium discoideum. A more complete alignment of the LARP1
DM15 region is shown in Supplementary Figure S4.
rich sequence present in the 5′TOP of RPS6, but not the
5′TOPs of PABPC1 or RPL13A. Our observations are con-
sistent with studies that have found varied LARP1 depen-
dence on TOPmRNA translation (5,12,16). It is likely that,
in the context of the entire LARP1 protein under differ-
ent physiological states, different RNA binding surfaces
might be revealed upon conformational change induced by
post-translational modification or by other binding part-
ners to modulate this RNA binding behavior. A deeper un-
derstanding of LARP1 binding selectivity awaits elucida-
tion of the LARP1 phospho-interactome in benign andma-
lignant cells.
The structure of the DM15 region from human LARP1
suggests that its unique amino acid sequence has evolved
into three HEAT-like helix-turn-helix folds for RNA bind-
ing. Thus, while the global fold is not unique, the surface
amino acids and lengths of the repeats are novel. As LARP1
has been implicated in cervical, breast, and liver cancers
through its interaction with cancer-sustaining mRNAs, the
DM15 repeat is a potential cancer drug target. Further, re-
peat proteins typically utilize their concave surfaces for in-
teractions with substrates or binding partners, suggesting
LARP1 has repurposed a commonly used protein-protein-
mediating fold for RNA binding.
With the exception of Ascomycota fungi, the DM15 re-
gion in all eukaryotic LARP1 sequences is composed of
three distinct but related repeats of A, B and C types (Fig-
ure 3, Supplementary Figure S4). A likely evolutionary sce-
nario to explain this situation is the expansion of a single
motif in the ancestral protein followed by the concerted evo-
lution of each repeat type to achieve specialization. In the
Ascomycota lineage (but not for other fungi lineages), selec-
tion pressure on the primary sequence of the C repeat (and
also to some extent of the A and B repeats) was released
and these sequences were allowed to drift from ancestral se-
quences. Despite this loss of primary sequence, the overall
Ascomycota DM15 structure is predicted to be conserved
(data not shown). These observations strongly suggest that
Ascomycota LARP1 possess a neofunctionalized DM15,
that might be functionally distinct from other eukaryotic
LARP1 proteins; the absence of conservation of key amino
acids shown here to be critical for RNA-binding (R840 and
Y883, Figures 1, 3 and Supplementary Figure S4) may indi-
cate that Ascomycota DM15 is no longer an RNA-binding
motif.
The structure of the DM15 region reveals a positively
charged patch containing conserved residues. Combined
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Figure 4. The concave surface of DM15 is conserved and positively charged. (A) Edge-on views of DM15 reveal that it assumes a curved structure.
Top, cartoon representation and coloured as in Figure 2A. Amino acids tested for their roles in binding the RPS6 5′TOP oligonucleotide are shown as
sticks. Middle, surface electrostatic representation as calculated by PyMOL (blue, electrostatically positive; red, electrostatically negative). Bottom, surface
representation coloured by conservation as calculated by Consurf (42) using alignment of DM15 sequences from Supplementary Figure S4 (white, less
conserved; dark green, more conserved). (B) View of the concave DM15 surface, coloured as in (A). (C) View of the convex DM15 surface, coloured as in
(A). The view in panel (B) is related to that in panel (C) by a 180◦ rotation about the x-axis.
tempting to speculate that this surface of the protein inter-
acts directly with RNA. While it is uncertain that LARP1
exists in the cell as a dimer, the crystallization of the DM15
region as a pseudo-symmetric dimer revealed a positively
charged cleft comprised of the concave surfaces of two
monomers, which allowed us to hone in on the proba-
ble RNA-binding amino acids. We reasoned that the co-
crystallized sulfate ion mimics the interactions of the phos-
phate backbone of a single-stranded RNA binding with an
electrostatically positive surface. Therefore, the position of
the co-crystallized sulfate ion, in addition to the pattern of
highly conserved hydrogen bonding donors and acceptors
lining the patch, were used to position a short polypyrimi-
dine sequence on the concave surface of the monomer (Fig-
ure 6). Since the DM15 construct interacts with neither
the poly(U) oligonucleotide nor the RPS6 TOP, we pre-
dict that the DM15 region of LARP1 interacts with both
the polypyrimidine and GC-rich regions of the 5′ end of
the RPS6 untranslated region, which are characteristic of
5′TOPs (18); nuclease protection assays (Supplementary
Figure S1) are consistent with this hypothesis.
In addition to binding RNA, LARP1 interacts with
mTOR (16), the serine/threonine kinase that integrates sig-
nals emanating from external cues to control cell growth
and proliferation via consensus TOR-signalling (TOS) mo-
tifs (47,48). mTOR exists in two complexes, mTORC1 and
mTORC2, which are comprised of different subunits that
impart substrate specificity for downstream signalling and
play roles in cellular localization and complex assembly
(49). A putative TOS-like sequence appears within the ver-
tebrate LARP1a primary structure in amino acids 928–931,
which are contained within the loop connecting 7 and 8
in the crystallized DM15 construct (Supplementary Figure
S6). The sequence of the putative TOS motif in LARP1 is
consistent with other identified TOS-like motifs (47). Some
of the amino acids in the putative LARP1 TOS-like se-
quence are conservative substitutions of canonical TOSmo-
tifs. For example, positions 1 and 3 in the LARP1 TOS-
like motif contain leucine and isoleucine, respectively, while
the consensus amino acids in these positions in most TOS-
motifs are phenylalanine and methionine (47). Mutagenesis
demonstrated that the substitution of leucine for phenylala-
nine at position 1 and isoleucine for methionine at position
3 of the TOS sequence still supports mTORC1 activity (47).
The mTORC1 complex is an obligate dimer (50) and
contains Raptor, a large protein that recognizes the TOS
motifs of mTOR substrates (47,48,51). The 3D structure
of mTORC1 elucidated by electron microscopy reveals a
symmetric dimer of the subunits of the complex organized
around a cleft of ∼40 × 28 A˚ (50). Interestingly, the puta-
tive TOS sequences within the non-crystallographic dimer
of the human DM15 crystal structure presented here are
approximately 50 A˚ apart. Therefore, if LARP1 exists as
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Figure 5. Dimerization of DM15 in the crystal. (A) A pseudo-twofold axis of rotation passes through the co-crystallized sulfate ion. The N- and C-termini
of each monomer are labelled. (B) A surface representation of the same view as in (A), coloured according to electrostatic potential. A positively charged
cleft is generated upon dimerization of DM15. (C) A zoomed view of the area in (A) bordered by the dotted box. The bound sulfate ion interacts directly
with K915 and Y911 on both molecules within the non-crystallographic pseudo-dimer.
Figure 6. Modelling of single-stranded oligopyrimidine RNA with conserved amino acids on the concave surface of the DM15 region. (A) A poly-
pyrimidine RNA sequence (CUUUU) was modelled onto the positive patch on the structure of DM15 based on shape and surface complementarity,
in addition to hydrogen bonding potential and sulfate ion positioning. (B) A zoomed view of the docked RNA boxed in panel (A). (C) The specific amino
acids used to facilitate RNAdocking in the structure are labelled. An additional residue, Y911 (shown in Figure 5) was also used to position the 5′ phosphate
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tion interface, each TOS motif in the conserved DM15 re-
gion can be recognized by Raptor simultaneously (Supple-
mentary Figure S7) to position the potential phosphory-
latable amino acids in LARP1 (52) within the active sites
of mTORC1 for modification. Many monomeric substrates
of mTOR exist in the cell (52), however, indicating that
LARP1 can be a substrate of mTORC1 regardless of its
oligomeric state.
Through its RNA- and mTORC1-binding abilities,
LARP1 plays an important role in the regulation of trans-
lation and ribosome biogenesis (5,16). The structure and
modelling of the LARP1-specific C-terminal motif, the
DM15 region, reveals structural insights into these cellu-
lar functions, and other RNA binding activities of LARP1,
while also providing the first view of a La-related protein
family-specific domain. By visualizing the organization of
the key amino acids predicted tomediatemRNAbinding by
LARP1, we provide potential therapeutic avenues for con-
trolling the pathogenic RNA binding activity of LARP1 in
cancer.
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